Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointments of Paula G. O’Connor, M.D., as chief medical officer and Pasit Phiasivongsa, Ph.D., as chief technical officer of Nurix.
“I am delighted to announce the promotions of both Paula and Pasit, which recognize their significant and ongoing leadership in advancing our pipeline of novel medicines and particularly in accelerating our NX-5948 program in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma,” said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. “As we look ahead to 2025 and beyond, having the right team in place is critical to maximize speed and success in the clinic and to foster a strong collaborative culture within Nurix.”
Dr. O’Connor joined Nurix in September 2022 and most recently served as executive vice president and head of clinical development. She trained as a hematologist-oncologist and has more than 15 years of drug development expertise. Prior to joining Nurix, Dr. O’Connor held senior level positions in clinical development and medical affairs at Protagonist Therapeutics, Oncopeptides, Inc., Coherus Biosciences, Medivation, Onyx, and Genentech. Dr. O’Connor completed her fellowships in hematology, oncology, and AIDS oncology at the combined programs of the Massachusetts General, Brigham and Women’s, and Dana Farber Cancer Institute. She holds a B.A. in psychology with a biology focus from Yale University and an M.D. from Stanford University.
Dr. Phiasivongsa joined Nurix in August 2022 and most recently served as executive vice president of technical operations. Prior to joining Nurix, he served as senior vice president, pharmaceutical development & manufacturing at Kronos Bio, where he led all CMC development, manufacturing, and supply chain-related activities. Before Kronos, Dr. Phiasivongsa served in senior CMC leadership roles at Principia Biopharma and Tobira Therapeutics. Early in his career, he held positions in drug discovery, development, and manufacturing. He is listed on 32 U.S.-issued patents and more than 40 patent applications. Dr. Phiasivongsa earned his B.S. in biochemistry and Ph.D. in pharmaceutical and chemical sciences from the University of the Pacific, Stockton.
SOURCE: GlobeNewswire